The U.S. imposition of 100% tariffs on patented pharmaceutical imports in 2025 presents both a threat and an opportunity for India's pharmaceutical industry. Critically analyse.

Q. The U.S. imposition of 100% tariffs on patented pharmaceutical imports in 2025 presents both a threat and an opportunity for India's pharmaceutical industry. Critically analyse. (15 marks, 250-350 words)

Announced in September 2025 and operationalised under Section 232 of the U.S. Trade Expansion Act, the 100% ad valorem tariff applies to patented pharmaceuticals, while generics and biosimilars remain exempt [1][2]. For India, therefore, the shock is less an immediate export loss than a structural constraint on its future direction.

The threat dimension - Concentration risk: the U.S. absorbs about 34% of India's pharmaceutical exports of $30.47 billion (FY2025), Europe another 19% — leaving policy leverage heavily one-sided [4]. - Legal durability: routed through a national-security investigation, the measure sidesteps ordinary trade-negotiation and WTO dispute timelines, and its scope can be widened by proclamation [2][3]. - Discriminatory tiering: EU, Japan, Korea and Switzerland face only 15%, and firms signing pricing and onshoring agreements pay 0% — India, without such an arrangement, bears the residual full rate [1]. - Value-chain penalty: the Economic Survey's stated shift from volume to complex generics, biosimilars and patented drugs is precisely the segment now taxed [5].

The opportunity dimension - The generics carve-out protects India's core business and improves its relative price advantage as branded drugs turn costlier in the U.S. [1]. - Onshoring and pricing agreements offer a negotiated route to zero duty for larger Indian firms [1]. - It accelerates market diversification — exports already reach 191 countries, and Europe, Africa and Latin America can absorb more [5]. - PLI for Pharmaceuticals (₹15,000 crore) and PLI for Bulk Drugs (₹6,940 crore, 41 bulk drugs) support both the move up the value chain and reduced API import dependence [6].

Critically, the opportunity is conditional: the exemption is administratively revocable, and onshoring shifts investment away from India.

India's response should combine bilateral negotiation for durable generic exemption, faster PLI implementation, and stronger quality compliance — converting an external shock into the discipline needed to become an innovation-led pharmacy of the world.

(~320 words)

Sources: 1. Fact Sheet: Imposing Tariffs on Patented Pharmaceutical Products — The White House — 100% tariff on patented drugs; generics/biosimilars exempt; 15% and 0% carve-outs 2. Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States (Proclamation 11020), Federal Register — Section 232 national-security basis and scope 3. Notice of Section 232 National Security Investigation of Imports of Pharmaceuticals, Federal Register (April 2025) — investigation route opened in 2025 4. Indian Pharmaceutical products are globally recognized, exports jumped over 9% this year — PIB — exports of $30.47 billion; U.S. 34%, Europe 19% share 5. Economic Survey 2025-26 Highlights India's Shift Toward High-Value Pharma and Innovation — PIB — volume-to-value shift; exports to 191 countries; complex generics and biosimilars 6. PLI Scheme for Pharmaceuticals — PIB — ₹15,000 crore pharmaceuticals outlay; ₹6,940 crore bulk drugs outlay for 41 bulk drugs